Pharmaceutical Executive-07-01-2010

Pharmaceutical Executive

In France, it took a president's keynote speech to underscore the government's new understanding that there is more to pharmaceuticals than cost-containment

Pharmaceutical Executive

Focus Reports discusses kep questions regarding France's pharma industry

Pharmaceutical Executive
Features

July 01, 2010

FDA's risk-reduction requirements could be the bridge to a bright new future for the pharma industry.

Pharmaceutical Executive

As they build market share, companies need a plan to limit exposure to steep fines and executive prosecutions.

Pharmaceutical Executive
Features

July 01, 2010

Outsourcing the sales representative function can help pharmaceutical companies build on their bottom line.

Pharmaceutical Executive
Washington Report

July 01, 2010

Drug prices, doctor payments, and FDA regulatory decisions are candidates for expanded disclosure.

Pharmaceutical Executive
Leadership

July 01, 2010

Once occupied by a single pharma leader, the roles of CEO, president, and board chairman are increasingly being separated. What's behind the trend?

Pharmaceutical Executive
Competition

July 01, 2010

Teva Pharmaceuticals has emerged as the industry's most formidable foe.

Pharmaceutical Executive

New strategies like augmented reality can increase patient compliance and knowledge.

Pharmaceutical Executive
Columns

July 01, 2010

Why do patients drop drug therapy after 12 months?

Pharmaceutical Executive
Features

July 01, 2010

Pharma companies are starting to get back in the game with increased advertising spend in 2009. Do we have economic recovery to thank, or is there a deeper cause?

Pharmaceutical Executive
From the Editor

July 01, 2010

If there was ever a justification for endorsing a "triple bottom line" strategy for measuring Big Pharma's investment performance, it's the BP crisis.

Pharmaceutical Executive

Why pharma sales representatives are still the best marketers and how to make them better.